Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Acquired hemophilia A Indication Strategy Report 2026: FVIII, Trials and Deals
23 July 2026
2026 Acquired hemophilia A strategy: epidemiology, FVIII biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Thrombotic thrombocytopenic purpura Indication Strategy Report 2026: ADAMTS13, Trials and Deals
23 July 2026
2026 Thrombotic thrombocytopenic purpura strategy: epidemiology, ADAMTS13 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cold agglutinin disease Indication Strategy Report 2026: C1s, Trials and Deals
23 July 2026
2026 Cold agglutinin disease strategy: epidemiology, C1s biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Evans syndrome Indication Strategy Report 2026: FcRn, Trials and Deals
23 July 2026
2026 Evans syndrome strategy: epidemiology, FcRn biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
POEMS syndrome Indication Strategy Report 2026: VEGF, Trials and Deals
23 July 2026
2026 POEMS syndrome strategy: epidemiology, VEGF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Castleman disease Indication Strategy Report 2026: IL-6, Trials and Deals
23 July 2026
2026 Castleman disease strategy: epidemiology, IL-6 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Rosai-Dorfman disease Indication Strategy Report 2026: MAP2K1, Trials and Deals
23 July 2026
2026 Rosai-Dorfman disease strategy: epidemiology, MAP2K1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Erdheim-Chester disease Indication Strategy Report 2026: BRAF, Trials and Deals
23 July 2026
2026 Erdheim-Chester disease strategy: epidemiology, BRAF biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
MDS/MPN with neutrophilia Indication Strategy Report 2026: JAK2, Trials and Deals
23 July 2026
2026 MDS/MPN with neutrophilia strategy: epidemiology, JAK2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Langerhans cell histiocytosis Indication Strategy Report 2026: BRAF, Trials and Deals
23 July 2026
2026 Langerhans cell histiocytosis strategy: epidemiology, BRAF biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Juvenile myelomonocytic leukemia Indication Strategy Report 2026: RAS, Trials and Deals
23 July 2026
2026 Juvenile myelomonocytic leukemia strategy: epidemiology, RAS biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Chronic myelomonocytic leukemia Indication Strategy Report 2026: RAS, Trials and Deals
23 July 2026
2026 Chronic myelomonocytic leukemia strategy: epidemiology, RAS biology, clinical competition, recent deals, unmet need and market attractiveness.